IndraLab

"However, both activation kinetics ( xref ; τ values at 40 mV: Kv7.4:CaM 1234 with 10 mM EGTA = 20.5 ± 2.5 ms; Kv7.4:CaM 1234 with 10 mM EGTA plus 3 mM CaCl 2 = 17.7 ± 2.6 ms; Kv7.4:CaM 1234 with 10 mM EGTA plus 6 mM CaCl 2 = 18.4 ± 2.2 ms) and voltage-dependent activation ( xref ; V 1/2 values at 40 mV: Kv7.4:CaM 1234 with 10 mM EGTA = −48.0 ± 1.4 mV; Kv7.4:CaM 1234 with 10 mM EGTA plus 3 mM CaCl 2 = −47.2 ± 1.8 mV; Kv7.4:CaM 1234 with 10 mM EGTA plus 6 mM CaCl 2 = −45.7 ± 1.1 mV) of Kv7.4:CaM 1234 remained unchanged when we used different pipette solutions."

"We also examined the effect of paroxetine on the voltage-dependent activation of Kv7.1, Kv7.4 and Kv7.5 channels at the concentrations near their IC 50 values."

"In addition, mutations at both positions did not affect voltage activation of KCNQ4, suggesting that these residues directly affect SsTx-KCNQ4 interaction."

"We also examined the effect of paroxetine on the voltage-dependent activation of Kv7.1, Kv7.4 and Kv7.5 channels at the concentrations near their IC values."

"Voltage-activated KCNQ4 currents were recorded from CHO–KCNQ4 cells by use of conventional patch clamp recordings in the whole-cell configuration using a single-electrode integrating voltage clamp amp[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

"Like Kv7.4:CaM 1234 , Kv7.4:CaM 3 showed insensitivity to the changing intracellular calcium levels, and both varying free calcium concentrations of the pipette solutions and application of BAPTA-AM have no effect on the activation rate ( xref ; τ values at 40 mV: Kv7.4:CaM 3 pretreated with 20 μM BAPTA-AM = 19.6 ± 2.1 ms; Kv7.4:CaM 3 with 10 mM EGTA = 19.2 ± 1.6 ms; Kv7.4:CaM 3 with 10 mM EGTA plus 3 mM CaCl 2 = 17.9 ± 1.4 ms; Kv7.4:CaM 3 with 10 mM EGTA plus 6 mM CaCl 2 = 18.1 ± 2.2 ms) or the voltage-dependent activation ( xref ; V 1/2 values: Kv7.4:CaM 3 pretreated with 20 μM BAPTA-AM = −45.3 ± 1.5 mV; Kv7.4:CaM 3 with 10 mM EGTA = −47.3 ± 1.7 mV; Kv7.4:CaM 3 with 10 mM EGTA plus 3 mM CaCl 2 = −48.5 ± 1.2 mV; Kv7.4:CaM 3 with 10 mM EGTA plus 6 mM CaCl 2 = −47.1 ± 1.3 mV) of Kv7.4:CaM 3 ."

"DFNA2 is a progressive deafness caused by mutations in the voltage activated potassium channel KCNQ4."

"Also, both BMS-204352 and retigabine potentiated the voltage activated KCNQ4 current at all potentials tested."